Kite Pharma (KITE) Tops Q3 EPS by 51c
Get Alerts KITE Hot Sheet
Join SI Premium – FREE
Kite Pharma (NASDAQ: KITE) reported Q3 EPS of ($1.10), $0.51 better than the analyst estimate of ($1.61). Revenue for the quarter came in at $7.34 million versus the consensus estimate of $4.94 million.
For earnings history and earnings-related data on Kite Pharma (KITE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Viasat stock rises on Raymond James target reiteration
- Leadership change and unchanged forecast send Avient stock tumbling 8%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share